[1] Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., et al. 2013.Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, andhumans. Sci Transl Med 5:209ra151.[2] Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., et al. 2015. Arationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.Nat Med 21:27-36.[3] Finan, B., Yang, B., Ottaway, N., Stemmer, K., Muller, T.D., Yi, C.X., et al. 2012. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847-1856.[4] Henderson, S.J., Konkar, A., Hornigold, D.C., Trevaskis, J.L., Jackson, R., Fritsch Fredin, M., et al. 2016. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18:1176-1190.[5] Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., et al. 2014. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63:3346-3358.[6] Donahey, J.C., van Dijk, G., Woods, S.C., Seeley, R.J. 1998. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 779:75-83.[7] Turton, M.D., O'Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K., et al. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72.[8] Furuse, M., Matsumoto, M., Okumura, J., Sugahara, K., Hasegawa, S. 1997. Intracerebroventricular injection of mammalian and chicken glucagon-like peptide-1 inhibits food intake of the neonatal chick. Brain Res 755:167-169.[9] Shousha, S., Nakahara, K., Nasu, T., Sakamoto, T., Murakami, N. 2007. Effect of glucagon-like peptide-1 and -2 on regulation of food intake, body temperature and locomotor activity in the Japanese quail. Neurosci Lett 415:102-107.[10] Raun, K., von Voss, P., Knudsen, L.B. 2007. Liraglutide, a once-daily human glucagonlike peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 15:1710-1716.[11] Renner, S., Blutke, A., Dobenecker, B., Dhom, G., Muller, T.D., Finan, B., et al. 2018. Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Gottingen minipigs. Mol Metab.[12] Elvert, R., Bossart, M., Herling, A.W., Weiss, T., Zhang, B., Kannt, A., et al. 2018. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. Endocrinology 159:3105-3119.[13] Scott, K.A., Moran, T.H. 2007. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293:R983-987.[14] Gutzwiller, J.P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., et al. 1999. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86.[15] Verdich, C., Flint, A., Gutzwiller, J.P., Naslund, E., Beglinger, C., Hellstrom, P.M., et al. 2001. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389.[16] Schlogl, H., Kabisch, S., Horstmann, A., Lohmann, G., Muller, K., Lepsien, J., et al. 2013. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 36:1933-1940.[17] Ten Kulve, J.S., Veltman, D.J., van Bloemendaal, L., Barkhof, F., Drent, M.L., Diamant, M., et al. 2016. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. Diabetes Care 39:214-221.[18] van Bloemendaal, L., RG, I.J., Ten Kulve, J.S., Barkhof, F., Konrad, R.J., Drent, M.L., et al. 2014. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63:4186-4196.[19] Clemmensen, C., Finan, B., Fischer, K., Tom, R.Z., Legutko, B., Sehrer, L., et al. 2015. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol Med 7:288-298.[20] Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sorensen, J., Cowley, M.A., Dalboge, L.S., et al. 2014. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124:4473-4488.[21] Kanoski, S.E., Fortin, S.M., Arnold, M., Grill, H.J., Hayes, M.R. 2011. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152:3103- 3112.[22] Swick, J.C., Alhadeff, A.L., Grill, H.J., Urrea, P., Lee, S.M., Roh, H., et al. 2015. Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia. Neuropsychopharmacology 40:2001-2014.[23] Baggio, L.L., Huang, Q., Brown, T.J., Drucker, D.J. 2004. Oxyntomodulin and glucagonlike peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558.[24] Labouesse, M.A., Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., Pacheco-Lopez, G. 2012. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol 24:1505-1516.[25] Baumgartner, I., Pacheco-Lopez, G., Ruttimann, E.B., Arnold, M., Asarian, L., Langhans, W., et al. 2010. Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 22:557-563.[26] Bucinskaite, V., Tolessa, T., Pedersen, J., Rydqvist, B., Zerihun, L., Holst, J.J., et al. 2009. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 21:978-e978.[27] Ruttimann, E.B., Arnold, M., Hillebrand, J.J., Geary, N., Langhans, W. 2009. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150:1174-1181.[28] Krieger, J.P., Arnold, M., Pettersen, K.G., Lossel, P., Langhans, W., Lee, S.J. 2016. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. Diabetes 65:34-43.[29] Plamboeck, A., Veedfald, S., Deacon, C.F., Hartmann, B., Wettergren, A., Svendsen, L.B., et al. 2013. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 304:G1117-1127.[30] Punjabi, M., Arnold, M., Ruttimann, E., Graber, M., Geary, N., Pacheco-Lopez, G., et al. 2014. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 155:1690-1699.[31] Kim, D.H., D'Alessio, D.A., Woods, S.C., Seeley, R.J. 2009. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept 155:110-114.[32] Tang-Christensen, M., Larsen, P.J., Goke, R., Fink-Jensen, A., Jessop, D.S., Moller, M., et al. 1996. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-856.[33] Larsen, P.J., Tang-Christensen, M., Jessop, D.S. 1997. Central administration ofglucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.Endocrinology 138:4445-4455.[34] Richards, P., Parker, H.E., Adriaenssens, A.E., Hodgson, J.M., Cork, S.C., Trapp, S., et al. 2014. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63:1224-1233.[35] Cork, S.C., Richards, J.E., Holt, M.K., Gribble, F.M., Reimann, F., Trapp, S. 2015. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4:718-731.[36] Jin, S.L., Han, V.K., Simmons, J.G., Towle, A.C., Lauder, J.M., Lund, P.K. 1988. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532.[37] Alhadeff, A.L., Mergler, B.D., Zimmer, D.J., Turner, C.A., Reiner, D.J., Schmidt, H.D., et al. 2017. Endogenous Glucagon-like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius is Required for Food Intake Control. Neuropsychopharmacology 42:1471-1479.[38] Barrera, J.G., Jones, K.R., Herman, J.P., D'Alessio, D.A., Woods, S.C., Seeley, R.J. 2011. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31:3904-3913.[39] Dickson, S.L., Shirazi, R.H., Hansson, C., Bergquist, F., Nissbrandt, H., Skibicka, K.P. 2012. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812-4820.[40] Terrill, S.J., Holt, M.K., Maske, C.B., Abrams, N., Reimann, F., Trapp, S., et al. 2019. Endogenous GLP-1 in lateral septum promotes satiety and suppresses motivation for food in mice. Physiol Behav 206:191-199.[41] Hayes, M.R., Leichner, T.M., Zhao, S., Lee, G.S., Chowansky, A., Zimmer, D., et al. 2011. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagonlike peptide-1 receptor activation. Cell Metab 13:320-330.[42] Barrington, P., Chien, J.Y., Tibaldi, F., Showalter, H.D., Schneck, K., Ellis, B. 2011. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 13:434-438.[43] Roberge, J.N., Brubaker, P.L. 1991. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128:3169-3174.[44] Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D.A., Sandoval, D.A., Seeley, R.J. 2014. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 124:2456-2463.[45] Burmeister, M.A., Ferre, T., Ayala, J.E., King, E.M., Holt, R.M., Ayala, J.E. 2012. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab 302:E334-343.[46] Seo, S., Ju, S., Chung, H., Lee, D., Park, S. 2008. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 55:867-874.[47] Burmeister, M.A., Ayala, J., Drucker, D.J., Ayala, J.E. 2013. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab 304:E677-685.[48] Alhadeff, A.L., Grill, H.J. 2014. Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. Am J Physiol Regul Integr Comp Physiol 307:R465-470.[49] Hayes, M.R., Bradley, L., Grill, H.J. 2009. Endogenous hindbrain glucagon-like peptide- 1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150:2654-2659.[50] Chaudhri, O.B., Parkinson, J.R., Kuo, Y.T., Druce, M.R., Herlihy, A.H., Bell, J.D., et al. 2006. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 350:298-306.[51] Parkinson, J.R., Chaudhri, O.B., Kuo, Y.T., Field, B.C., Herlihy, A.H., Dhillo, W.S., et al. 2009. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 44:1022-1031.[52] Schick, R.R., Zimmermann, J.P., vorm Walde, T., Schusdziarra, V. 2003. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 284:R1427-1435.[53] McMahon, L.R., Wellman, P.J. 1997. Decreased intake of a liquid diet in nonfooddeprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav 58:673-677.[54] McMahon, L.R., Wellman, P.J. 1998. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 274:R23-29.[55] Thiele, T.E., Roitman, M.F., Bernstein, I.L. 1996. c-Fos induction in rat brainstem in response to ethanol- and lithium chloride-induced conditioned taste aversions. Alcohol Clin Exp Res 20:1023-1028.[56] Mitchell, D., Wells, C., Hoch, N., Lind, K., Woods, S.C., Mitchell, L.K. 1976. Poisoninduced pica in rats. Physiol Behav 17:691-697.[57] Pelchat, M.L., Grill, H.J., Rozin, P., Jacobs, J. 1983. Quality of acquired responses to tastes by Rattus norvegicus depends on type of associated discomfort. J Comp Psychol 97:140-153.[58] Swank, M.W., Bernstein, I.L. 1994. c-Fos induction in response to a conditioned stimulus after single trial taste aversion learning. Brain Res 636:202-208.[59] Thiele, T.E., Seeley, R.J., D'Alessio, D., Eng, J., Bernstein, I.L., Woods, S.C., et al. 1998. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801:164-170.[60] Meachum, C.L., Bernstein, I.L. 1992. Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav 52:895-899.[61] Bernstein, I.L., Chavez, M., Allen, D., Taylor, E.M. 1992. Area postrema mediation of physiological and behavioral effects of lithium chloride in the rat. Brain Res 575:132-137.[62] O'Shea, D., Gunn, I., Chen, X., Bloom, S., Herbert, J. 1996. A role for central glucagonlike peptide-1 in temperature regulation. Neuroreport 7:830-832.[63] Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19:336-347.[64] Alhadeff, A.L., Baird, J.P., Swick, J.C., Hayes, M.R., Grill, H.J. 2014. Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology 39:2233-2243.[65] Alhadeff, A.L., Rupprecht, L.E., Hayes, M.R. 2012. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153:647-658.[66] Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang-Christensen, M., Knudsen, L.B. 2012. Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight. Diabetes Obes Metab 14:531-538.[67] ten Kulve, J.S., Veltman, D.J., van Bloemendaal, L., Barkhof, F., Deacon, C.F., Holst, J.J., et al. 2015. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 58:2688-2698.[68] Dossat, A.M., Lilly, N., Kay, K., Williams, D.L. 2011. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 31:14453-14457.[69] Merchenthaler, I., Lane, M., Shughrue, P. 1999. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280.[70] Decarie-Spain, L., Fisette, A., Zhu, Z., Yang, B., DiMarchi, R.D., Tschop, M.H., et al. 2019. GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacology 151:55-63.[71] Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J.A., Jerlhag, E. 2013. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259-1270.[72] Sirohi, S., Schurdak, J.D., Seeley, R.J., Benoit, S.C., Davis, J.F. 2016. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav 161:140-144.[73] Dossat, A.M., Diaz, R., Gallo, L., Panagos, A., Kay, K., Williams, D.L. 2013. Nucleusaccumbens GLP-1 receptors influence meal size and palatability. Am J Physiol Endocrinol Metab 304:E1314-1320.[74] Hunter, K., Holscher, C. 2012. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33.[75] Kastin, A.J., Akerstrom, V. 2003. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27:313-318.[76] Kastin, A.J., Akerstrom, V., Pan, W. 2002. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:7-14.[77] Salinas, C.B.G., Lu, T.T., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A.J., et al. 2018. Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment. Sci Rep 8:10310.[78] Gutzwiller, J.P., Hruz, P., Huber, A.R., Hamel, C., Zehnder, C., Drewe, J., et al. 2006. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73:142-150.[79] McKay, N.J., Kanoski, S.E., Hayes, M.R., Daniels, D. 2011. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol 301:R1755-1764.[80] Tang-Christensen, M., Vrang, N., Larsen, P.J. 1998. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47:530-537.[81] Moreno, C., Mistry, M., Roman, R.J. 2002. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434:163-167.[82] Crajoinas, R.O., Oricchio, F.T., Pessoa, T.D., Pacheco, B.P., Lessa, L.M., Malnic, G., et al. 2011. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301:F355-363.[83] Gutzwiller, J.P., Tschopp, S., Bock, A., Zehnder, C.E., Huber, A.R., Kreyenbuehl, M., et al. 2004. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulinresistant obese men. J Clin Endocrinol Metab 89:3055-3061.[84] Skov, J., Dejgaard, A., Frokiaer, J., Holst, J.J., Jonassen, T., Rittig, S., et al. 2013. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensinaldosterone system in healthy men. J Clin Endocrinol Metab 98:E664-671.[85] Skov, J., Pedersen, M., Holst, J.J., Madsen, B., Goetze, J.P., Rittig, S., et al. 2016. Shortterm effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18:581-589.[86] Tonneijck, L., Smits, M.M., Muskiet, M.H., Hoekstra, T., Kramer, M.H., Danser, A.H., et al. 2016. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 39:2042-2050.[87] Lovshin, J.A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., Drucker, D.J. 2015. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38:132- 139.[88] Schlatter, P., Beglinger, C., Drewe, J., Gutmann, H. 2007. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141:120-128.[89] Pacheco, B.P., Crajoinas, R.O., Couto, G.K., Davel, A.P., Lessa, L.M., Rossoni, L.V., et al. 2011. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 29:520-528.[90] Carraro-Lacroix, L.R., Malnic, G., Girardi, A.C. 2009. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297:F1647-1655.[91] Farah, L.X., Valentini, V., Pessoa, T.D., Malnic, G., McDonough, A.A., Girardi, A.C. 2016. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am J Physiol Renal Physiol 310:F123-127.[92] Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., et al. 2013. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19:567-575.[93] Cannon, B., Nedergaard, J. 2011. Nonshivering thermogenesis and its adequate measurement in metabolic studies. J Exp Biol 214:242-253.[94] Morrison, S.F., Madden, C.J., Tupone, D. 2014. Central neural regulation of brown adipose tissue thermogenesis and energy expenditure. Cell Metab 19:741-756.[95] Lee, S.J., Sanchez-Watts, G., Krieger, J.P., Pignalosa, A., Norell, P.N., Cortella, A., et al. 2018. Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Mol Metab 11:33-46.[96] Shi, X., Chacko, S., Li, F., Li, D., Burrin, D., Chan, L., et al. 2017. Acute activation of GLP- 1-expressing neurons promotes glucose homeostasis and insulin sensitivity. Mol Metab 6:1350-1359.[97] Holt, M.K., Richards, J.E., Cook, D.R., Brierley, D.I., Williams, D.L., Reimann, F., et al. 2019. Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food. Diabetes 68:21-33.[98] Gaykema, R.P., Newmyer, B.A., Ottolini, M., Raje, V., Warthen, D.M., Lambeth, P.S., et al. 2017. Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. J Clin Invest 127:1031-1045.[99] Hwa, J.J., Ghibaudi, L., Williams, P., Witten, M.B., Tedesco, R., Strader, C.D. 1998. Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 19:869-875.[100] Lockie, S.H., Heppner, K.M., Chaudhary, N., Chabenne, J.R., Morgan, D.A., Veyrat-Durebex, C., et al. 2012. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61:2753-2762.[101] Osaka, T., Endo, M., Yamakawa, M., Inoue, S. 2005. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26:1623-1631.[102] Krieger, J.P., Santos da Conceicao, E.P., Sanchez-Watts, G., Arnold, M., Pettersen, K.G., Mohammed, M., et al. 2018. Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. Am J Physiol Regul Integr Comp Physiol 315:R708-R720.[103] Cegla, J., Troke, R.C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K.A., et al. 2014.Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63:3711-3720.[104] Bergmann, N.C., Lund, A., Gasbjerg, L.S., Meessen, E.C.E., Andersen, M.M., Bergmann, S., et al. 2019. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia 62:665-675.[105] Willms, B., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W., Nauck, M.A. 1996. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332.[106] Linnebjerg, H., Park, S., Kothare, P.A., Trautmann, M.E., Mace, K., Fineman, M., et al. 2008. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 151:123-129.[107] Tatarkiewicz, K., Sablan, E.J., Polizzi, C.J., Villescaz, C., Parkes, D.G. 2014. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. Am J Physiol Regul Integr Comp Physiol 306:R490-498.[108] Giralt, M., Vergara, P. 1998. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat. Regul Pept 74:19-25.[109] Imeryuz, N., Yegen, B.C., Bozkurt, A., Coskun, T., Villanueva-Penacarrillo, M.L., Ulusoy, N.B. 1997. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-927.[110] Anvari, M., Paterson, C.A., Daniel, E.E., McDonald, T.J. 1998. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci 43:1133-1140.[111] Nagell, C.F., Wettergren, A., Orskov, C., Holst, J.J. 2006. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41:667-672.[112] Wettergren, A., Wojdemann, M., Holst, J.J. 1998. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275:G984-992.[113] Nauck, M.A., Kemmeries, G., Holst, J.J., Meier, J.J. 2011. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60:1561-1565.[114] Hayes, M.R., Skibicka, K.P., Grill, H.J. 2008. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149:4059-4068.[115] Krieger, J.P., Arnold, M., Pettersen, K.G., Lossel, P., Langhans, W., Lee, S.J. 2016. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. Diabetes 65:34-43.[116] Wettergren, A., Wojdemann, M., Meisner, S., Stadil, F., Holst, J.J. 1997. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597-601.[117] Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., et al. 2017. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2:890-899.[118] Creutzfeldt, W.O., Kleine, N., Willms, B., Orskov, C., Holst, J.J., Nauck, M.A. 1996. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586.[119] Gutniak, M., Orskov, C., Holst, J.J., Ahren, B., Efendic, S. 1992. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322.“此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场”投稿/转载/商务合作,请联系:pengsanmei@yxj.org.cn